- Sarcoma
  - Soft tissue sarcoma
    - **10556**: Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
  - Alveolar soft part sarcoma
    - **10504:** A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
  - Potentially resectable: liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma (UPS)/ malignant fibrous histiosarcoma (MFH)
    - **10563:** A phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas
  - Chondrosarcoma
    - **10330:** A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
  - NUT Carcinoma
    - **10507:** A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma
    - **10509:** A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
  - Rb+ Sarcoma
    - ***▼10657:** Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Retinoblastoma (Rb)+ Sarcomas

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 24, 2024